Aldeyra Therapeutics: Reproxalap's March 2026 FDA Decision Is The Defining Catalyst

Aldeyra ’s Reproxalap is the core catalyst. The FDA will make its decision on this asset by March 16, 2026, after a ...
Young and the Invested on MSN

7 best Vanguard dividend funds for 2026

VDADX has an exchange-traded version, the Vanguard Dividend Appreciation ETF (VIG, 0.05% expense ratio), that you can buy for ...

Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Di…

FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 ...

Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Pre…

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has ...